Skip to main content


Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

Fig. 1

Test with a standardized 500 calories mixed breakfast for 5 h: blood glucose, insulin, proinsulin and glucagon levels. N1 and N2 before and after 4 months of nateglinide therapy. R1 and R2 before and after 4 months of rosiglitazone therapy. Hatched area data of normal controls. Data were analyzed by the area under the curve using the trapezoidal rule and by Wilcoxon test for every time for the 5 h duration (p < 0.05)

Back to article page